Bullish
Johnson & Johnson's stock rises 1.1% to $273.11 amid positive pipeline developments
In the past 24 hours, Johnson & Johnson's stock increased by 1.1%, closing at $273.11. This uptick is attributed to recent positive developments in the company's pharmaceutical pipeline, including the European Commission's approval of a TECVAYLI combination for multiple myeloma and the FDA's approval of Imaavy for warm autoimmune hemolytic anemia. These advancements are expected to bolster future pharmaceutical sales and offset revenue declines from older drugs.
Key points
- European Commission approves TECVAYLI combination for multiple myeloma, expanding J&J's oncology portfolio.
- FDA approves Imaavy for warm autoimmune hemolytic anemia, addressing an unmet need in a rare disease.
- J&J's proposed $5.5 billion talc settlement may improve liability visibility but doesn't fully resolve legal exposure.
- Louisiana jury awards $10 million in talc-related mesothelioma case, highlighting ongoing litigation risks.
Sources
- Johnson & Johnson (NYSE:JNJ) Shares Up 1.1% - What's Next?MarketBeat · August 24, 2026
- Johnson & Johnson (NYSE:JNJ) Shares Up 1.1% - What's Next?MarketBeat · August 24, 2026
- Johnson & Johnson (NYSE:JNJ) Shares Up 1.1% - What's Next?MarketBeat · August 24, 2026
- Johnson & Johnson (NYSE:JNJ) Shares Up 1.1% - What's Next?MarketBeat · August 24, 2026
AI-generated from public news sources. Not financial advice.
